Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions on using enzalutamide. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.
We reviewed the evidence in January 2019. We found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
There is a simple discount patient access scheme for enzalutamide. Contact email@example.com for details.